[A23-11] Dapagliflozin (heart failure with preserved ejection fraction) – Benefit assessment according to §35a Social Code Book V
Last updated 17.08.2023
Project no.:
A23-11
Commission:
Commission awarded on 27.02.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Heart and circulation
Indication:
Adults with symptomatic chronic heart failure with left ventricular ejection fraction > 40%
Result of dossier assessment:
- Without type 2 diabetes mellitus and without chronic kidney disease: hint of non-quantifiable added benefit
- With/without type 2 diabetes mellitus and with chronic kidney disease: hint of non-quantifiable added benefit
- With type 2 diabetes mellitus and without chronic kidney disease: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2023-08-17 A G-BA decision was published.